Paper Details

  1. Home
  2. Paper Details

Methotrexate for induction of remission in refractory Crohn's disease.

Author: AlfadhliA A F, FeaganB G, McDonaldJ W D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Corticosteroids are effective for Crohn's disease but cause side effects and about 20% of patients relapse when they stop taking them. Methotrexate, a drug successful for rheumatoid arthritis, has become a main alternative to other medications for Crohn's disease, but its effectiveness hasn't been thoroughly reviewed.
Paper Details　
Original Abstract of the Article :
Although corticosteroids are effective for induction of remission of Crohn's disease, approximately 20% of patients who respond relapse when steroids are withdrawn and become steroid dependent (Binder 1985). Furthermore, corticosteroids exhibit significant adverse effects. The success of methotrexat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD003459.pub2

データ提供：米国国立医学図書館（NLM）

Methotrexate for Induction of Remission in Refractory Crohn's Disease

This review examines the use of methotrexate, a medication commonly used to treat rheumatoid arthritis, for inducing remission in patients with refractory Crohn's disease, a chronic inflammatory bowel disease. The authors review the available literature on methotrexate's effectiveness in managing refractory Crohn's disease, an area where corticosteroids, the traditional treatment, often fail to provide lasting remission.

Methotrexate: A Potential Treatment for Refractory Crohn's Disease

The review highlights the potential of methotrexate as an alternative to azathioprine/6MP therapy for inducing remission in refractory Crohn's disease. While methotrexate has shown promise in managing Crohn's disease, the authors emphasize the need for further research to establish its long-term efficacy and optimal use in this specific patient population.

Managing Crohn's Disease: Navigating the Desert of Inflammation

Imagine a desert landscape where the shifting sands represent the unpredictable nature of Crohn's disease. This review offers a glimpse into the potential of methotrexate as a tool for managing refractory Crohn's disease, providing a potential oasis of relief for patients who have not responded to traditional treatments. However, it is crucial to consult with a healthcare professional for proper diagnosis and management of Crohn's disease.

Dr.Camel's Conclusion

This review explores the potential of methotrexate as a treatment option for refractory Crohn's disease. While the findings suggest that methotrexate may be effective in inducing remission, further research is needed to establish its long-term efficacy and optimal use in this specific patient population.

Date :
  1. Date Completed 2005-05-27
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

15674908

DOI: Digital Object Identifier

10.1002/14651858.CD003459.pub2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.